Bristol Myers Squibb & Eli Lilly and Company
11 shared events · Importance 4 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Bristol Myers Squibb: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Eli Lilly and Company: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb is the primary investor, committing $2.3 billion to build a new manufacturing campus in United States — Houston. This investment is part of its $40 billion U.S. expansion plan and is expected to enhance its manufacturing capabilities and support future drug production.
Eli Lilly and Company: Eli Lilly is mentioned as another pharmaceutical company investing in the same Generation Park area, with a $6.5 billion plant. This highlights the region's growing life sciences cluster but is not directly impacted by BMS's announcement.
Aug 10, 2026 · 20 articles
Tech
Bristol Myers Squibb: Bristol Myers Squibb is a consortium member. The publication may influence its approach to cognitive endpoints in neurodegenerative disease trials.
Eli Lilly and Company: Eli Lilly is a consortium member. The study's results could support its use of multimodal home-based assessments in CNS trials.
Aug 18, 2026 · 6 articles
Domestic
Bristol Myers Squibb: Bristol Myers Squibb, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Eli Lilly and Company: Eli Lilly and Company, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb supported Gilead's appeal, gaining from the precedent that reduces innovation-related legal risks.
Eli Lilly and Company: Eli Lilly supported Gilead's appeal, benefiting from the ruling that protects drugmakers from duty-to-innovate claims.
Aug 03, 2026 · 6 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb originally licensed bempikibart to Q32 Bio; no direct impact from this event.
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Jul 13, 2026 · 6 articles
Business
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Eli Lilly and Company: Eli Lilly is mentioned as a prior acquirer of Point Biopharma and as a former partner with Lantheus on a PSMA-directed therapeutic that was abandoned after an unfavorable trial.
Aug 03, 2026 · 7 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb has a presence in Hyderabad with R&D and capability centers, contributing to India — Telangana's life sciences ecosystem.
Jan 21, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Bristol Myers Squibb and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard